Media

Oncopeptides presents new data highlighting treatment benefits of Pepaxti in high-risk multiple myeloma patients at the COMy Congress

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

Vicore Expands and Strengthens its Board of Directors

Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Fusion Pharmaceuticals Announces First Patient Dosed In The Phase 2 Portion Of The AlphaBreak Trial Evaluating FPI-2265 In Metastatic Castration-Resistant Prostate Cancer

Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024

Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results And Announces Clinical Program Updates

Oncopeptides publishes final outcome in the fully guaranteed rights issue

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Vicore Pharma – Interim report January-March 2024